Tiverton Asset Management’s Myriad Genetics MYGN Stock Holding History

Tiverton Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-123,800	Closed	-$2.55M	–	194
2016 Q3	$2.55M	Sell	123,800 -265,178	-68%	-$6.73M	0.2%	118
2016 Q2	$21.5M	Buy	388,978 +206,204	+113%	+$7.16M	0.9%	37
2016 Q1	$6.84M	Sell	182,774 -17,226	-9%	-$649K	0.23%	101
2015 Q4	$8.63M	Sell	200,000 -50,000	-20%	-$2.11M	0.27%	96
2015 Q3	$9.37M	Sell	250,000 -225,000	-47%	-$7.99M	0.21%	103
2015 Q2	$16.1M	Hold	475,000	–	–	0.32%	88
2015 Q1	$16.8M	Hold	475,000	–	–	0.34%	85
2014 Q4	$16.2M	Hold	475,000	–	–	0.34%	85
2014 Q3	$18.3M	Sell	475,000 -25,000	-5%	-$933K	0.42%	78
2014 Q2	$19.5M	Sell	500,000 -1,157,700	-70%	-$43.1M	0.44%	79
2014 Q1	$56.7M	Sell	1,657,700 -122,500	-7%	-$3.8M	1.23%	28
2013 Q4	$37.4M	Hold	1,780,200	–	–	0.83%	54
2013 Q3	$41.8M	Hold	1,780,200	–	–	1.01%	40
2013 Q2	$47.8M	Buy	+1,780,200	New	+$51.6M	1.24%	28

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Tiverton Asset Management's MYGN Position: Q4 2016 in Review

Tiverton Asset Management sold out of Myriad Genetics (MYGN) in Q4 2016, closing a stake of 123,800 shares — an estimated $2.55M sold.

Tiverton Asset Management first reported a position in MYGN in Q2 2013 and held it in 14 quarters. The position peaked at $56.7M in Q1 2014. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

Tiverton Asset Management reported no remaining Myriad Genetics position as of Q4 2016 after selling out during the quarter.
Tiverton Asset Management sold 123,800 Myriad Genetics shares in Q4 2016, an estimated $2.55M.
Tiverton Asset Management first reported a position in Myriad Genetics in Q2 2013 and held it in 14 quarters.
Tiverton Asset Management's Myriad Genetics position peaked at $56.7M in Q1 2014.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on Tiverton Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.